Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian Cancer
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Pazopanib is an oral drug that blocks several targets involved in angiogenesis. In the trial, the median time to progression-free survival in the pazopanib arm was 17.9 months compared to 12.3 months for placebo. This trial provides further evidence that angiogenesis is an important target in the treatment of patients with ovarian cancer, Aghajanian notes.
- A phase III randomized trial compared the oral targeted drug pazopanib to placebo in ovarian cancer
- The median time to progression-free survival in the pazopanib arm was 17.9 months compared to 12.3 months for placebo
- This trial provides further evidence that angiogenesis is an important target in the treatment of patients with ovarian cancer, Aghajanian notes
<<<
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
